Literature DB >> 3501545

Pharmacokinetics of leucovorin (D,L-5-formyltetrahydrofolate) after intravenous injection and constant intravenous infusion.

J A Straw1, E M Newman, J H Doroshow.   

Abstract

The pharmacokinetics of the active and inactive diastereoisomers of leucovorin and its active metabolite, 5-methyltetrahydrofolate (5-CH3-THF) were studied after iv injection of leucovorin in normal human subjects at a dose of 28 mg/m2, and in patients given 500 mg/m2 daily by constant iv infusion for a 5.5 day period. In both studies the plasma half-life (t1/2) of the active isomer, L-formyltetrahydrofolate (CHO-THF), was only 32 to 35 minutes, whereas the inactive isomer, D-CHO-THF had a plasma t 1/2 of 352 to 485 minutes. During constant infusion, the plasma levels reached plateaus of 2.33 and 37.5 microM for L-CHO-THF and D-CHO-THF, respectively. The inactive isomer was cleared from plasma only by urinary excretion of the unchanged drug. The active isomer was also excreted unchanged in the urine but in addition was extensively metabolized to the active metabolite L-5-CH3-THF. The active metabolite achieved a plasma level of 4.85 microM during constant infusion and appeared to have a longer t 1/2 after constant infusion than was observed after iv injection. Furthermore a larger apparent volume of distribution (Vd) of 5-CH3-THF was obtained in the constant infusion study. These findings suggest that constant iv infusion of large doses of leucovorin can considerably expand the intracellular pools of active folate. The consequence of the extensive accumulation of the inactive isomer, D-CHO-THF, is not known. However, the small Vd of D-CHO-THF suggests that it does not extensively accumulate in tissues.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3501545

Source DB:  PubMed          Journal:  NCI Monogr        ISSN: 0893-2751


  7 in total

1.  Pharmacokinetics of reduced folates after short-term infusion of d, 1-folinic acid.

Authors:  A Schalhorn; M Kühl; G Stupp-Poutot; V Nüssler
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate.

Authors:  P O Greiner; J Zittoun; J Marquet; J M Cheron
Journal:  Br J Clin Pharmacol       Date:  1989-09       Impact factor: 4.335

3.  Pharmacokinetic comparison of leucovorin and levoleucovorin.

Authors:  J Zittoun; A P Tonelli; J Marquet; E De Gialluly; C Hancock; A Yacobi; J B Johnson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  The pharmacokinetics of reduced folates after intraperitoneal and intravenous administration of racemic [6S,R]-folinic acid.

Authors:  J H Sips; O van Tellingen; W J Nooijen; S Rodenhuis; W J Ten Bokkel Huinink; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Intracellular metabolism of 5-methyltetrahydrofolate and 5-formyltetrahydrofolate in a human breast-cancer cell line.

Authors:  D M Voeller; C J Allegra
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

6.  Comparative effect of 6S, 6R and 6RS leucovorin on methotrexate rescue and on modulation of 5-fluorouracil.

Authors:  J Zittoun; J Marquet; J J Pilorget; C Tonetti; E De Gialluly
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

7.  Changes in intracellular folate metabolism during high-dose methotrexate and Leucovorin rescue therapy in children with acute lymphoblastic leukemia.

Authors:  Natanja Oosterom; Robert de Jonge; Desiree E C Smith; Rob Pieters; Wim J E Tissing; Marta Fiocco; Bertrand D van Zelst; Marry M van den Heuvel-Eibrink; Sandra G Heil
Journal:  PLoS One       Date:  2019-09-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.